EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis

Binlong Chen, Yanzhong Zhao, Zichang Lin, Jiahao Liang, Jialong Fan, Yanyan Huang, Leye He, Bin Liu

Journal of Pharmaceutical Analysis · 2024-05 · 14 (5) · 100904

DOI: 10.1016/j.jpha.2023.11.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Analysis, 2024-05. Verfasst von Binlong Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Health Management Center, The Third Xiangya Hospital, Central South University, Changsha, 410013, China. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Due to the non-targeted release and low solubility of anti-gastric cancer agent, apatinib (Apa), a first-line drug with long-term usage in a high dosage often induces multi-drug resistance and causes serious side effects. In order to avoid these drawbacks, lipid-film-coated Prussian blue nanoparticles (PB NPs) with hyaluronan (HA) modification was used for Apa loading to improve its solubility and targeting ability. Furthermore, anti-tumor compound of gamabufotalin (CS-6) was selected as a partner of Apa with reducing dosage for combinational gastric therapy. Thus, HA-Apa-Lip@PB-CS-6 NPs were constructed to synchronously transport the two drugs into tumor tissue. In vitro assay indicated that HA-Apa-Lip@PB-CS-6 NPs can synergistically inhibit proliferation and invasion/metastasis of BGC-823 cells via downregulating vascular endothelial growth factor receptor (VEGFR) and matrix metalloproteinase-9 (MMP-9). In vivo assay demonstrated strongest anti-tumor growth and liver metastasis of HA-Apa-Lip@PB-CS-6 NPs administration in BGC-823 cells-bearing mice compared with other groups due to the excellent penetration in tumor tissues and outstanding synergistic effects. In summary, we have successfully developed a new nanocomplexes for synchronous Apa/CS-6 delivery and synergistic gastric cancer (GC) therapy.

Schlagwörter

Stichwörter der Autor:innen

ApatinibGamabufotalinGastric cancerLipid/Prussian blue nanoparticles

Autor:innen und Institutionen

  • Health Management Center, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.
  • Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.
  • Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.
  • College of Biology, Hunan University, Changsha, 410082, China.

Zitieren

APA

Chen, B., Zhao, Y., Lin, Z., Liang, J., Fan, J., Huang, Y., He, L., & Liu, B. (2024). Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis. Journal of Pharmaceutical Analysis, 14(5), 100904. https://doi.org/10.1016/j.jpha.2023.11.011

Vancouver

Chen B, Zhao Y, Lin Z, Liang J, Fan J, Huang Y, et al. Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis. Journal of Pharmaceutical Analysis. 2024;14(5):100904. doi:10.1016/j.jpha.2023.11.011

BibTeX
@article{Chen2024,
  author = {Chen, Binlong and Zhao, Yanzhong and Lin, Zichang and Liang, Jiahao and Fan, Jialong and Huang, Yanyan and He, Leye and Liu, Bin},
  title = {Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis},
  journal = {Journal of Pharmaceutical Analysis},
  year = {2024},
  volume = {14},
  number = {5},
  pages = {100904},
  doi = {10.1016/j.jpha.2023.11.011}
}
Kostenlos starten →